1.89 USD
↘ 0.00 (0.16%)PRE MARKET (AS OF 07:13 AM EDT)
enGene Therapeutics Inc. Common Stock
ENGNNASDAQ • USD
Market: OPEN
enGene Therapeutics Inc. Common Stock (ENGN) is currently trading at $1.89. There is a divergence between signals — technical indicators rate "Strong Buy" but underlying fundamentals lean "Sell". Notable factors include a concerning Altman Z-Score in the distress zone, a weak Piotroski F-Score of 0/9, negative Return on Equity and a bearish Death Cross on the long-term moving averages. The stock looks compelling on valuation, with multiples below sector averages across P/E, P/B, and EV/EBITDA.
Technical & fundamental data as of Sep 15, 2026.
Open?$1.90
High?$1.90
Low?$1.89
Prev. Close?$1.89
Volume?668
Avg. Volume?704.6K
VWAP?$1.90
Rel. Volume?0.00x
Bid / Ask
Bid?$1.59 × 100
Ask?$2.14 × 100
Spread?$0.55
Midpoint?$1.87
Valuation & Ratios
Market Cap?126.7M
Shares Out?67.0M
Float?44.1M
Float %?65.8%
P/E Ratio?N/A
P/B Ratio?0.55
EPS?-$1.95
Dividend?0.00%
Ex-Dividend?N/A
News
Profile
enGene Therapeutics Inc is a clinical-stage biotechnology company mainstreaming gene therapy through the delivery of therapeutics to mucosal tissues and other organs, to create new ways to address diseases with high clinical needs. Its pioneering program is detalimogene voraplasmid (also known as detalimogene) for patients with Non-Muscle Invasive Bladder Cancer (NMIBC), a disease with a high clinical burden. Detalimogene is being evaluated in the ongoing multi-cohort LEGEND Phase 2 trial, which includes a pivotal cohort studying detalimogene in high-risk, Bacillus Calmette-Guerin (BCG)-unresponsive patients with carcinoma in situ (CIS) with or without concomitant papillary disease. It is developed using enGene's proprietary Dually Derivatized Oligochitosan (DDX) platform.
Themes
Employees
82
Market Cap
125.3M
Industry
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Website
Listed
2023-11-01
Address
4868 RUE LEVY, SUITE 220
SAINT-LAURENT,
Phone: (514) 332-4888
SAINT-LAURENT,
Phone: (514) 332-4888
Technical OutlookStrong Buy
Strong SellNeutralStrong Buy
Long-Term (Tide)?▲ Bullish(+1/3)
Medium-Term (Wave)?▲ Bullish(+3/3)
Short-Term (Ripple)?▲ Bullish(+3/3)
MA Alignment?Mixed
Full Technical Analysis →Fundamental OutlookSell
Strong SellNeutralStrong Buy
F-Score?3
Z-Score?0
Momentum?50
Short Sent.?94
Piotroski F-Score?0/9Weak
Altman Z-Score?-1.47Distress
Confidence?43%Low
Short InterestLow
Short % of Float?2.78%Low
Short Interest?1.2M
Days to Cover?1.8
Free Float44.1M
Avg Daily Volume688.1K
Settlement Date2026-08-31
Financial Health
Current Ratio?10.21Strong
Quick Ratio?10.21Strong
Cash Ratio?1.51Strong
Debt/Equity?0.11Low
ValuationATTRACTIVELY VALUEDvs 1 peers + S&P 500
Score100/100
P/E?N/A▾
P/B?0.55CHEAP▾
Peers100
S&P97
P/S?N/A▾
P/FCF?N/A▾
EV/EBITDA?-0.8CHEAP▾
S&P97
EV/Sales?N/A▾
Returns & Efficiency
ROE?-56.6%WEAK▾
S&P3
ROA?-45.2%WEAK▾
S&P3
Cash Flow & Enterprise
FCF?$-103997000
Enterprise Value?$111.0M
Fundamentals ratios updated end of day